GLP-1 and Cardiovascular Health: What the SELECT Trial Changed in 2026

For years, the conversation around GLP-1 medications focused almost entirely on weight loss and blood sugar control. That picture is now complete. A growing body of evidence places cardiovascular protection at the center of what these medications can do, and the 2026 data from the SELECT trial extension has given doctors and patients the clearest reason yet to pay attention.

The SELECT Trial Explained

SELECT stands for Semaglutide Effects on Cardiovascular Outcomes in People with Overweight or Obesity. The trial enrolled more than 17,000 adults across 41 countries, all of them living with cardiovascular disease but without a diabetes diagnosis. Participants received weekly injections of semaglutide, the same compound found in Ozempic and Wegovy, or a placebo. Researchers then tracked major adverse cardiovascular events — heart attacks, strokes, and cardiovascular death — over a period that now stretches well beyond the original study window.

The initial results, released in 2023, showed a 20% reduction in MACE among those taking semaglutide. That number alone was remarkable. It meant that a weight loss medication was outperforming many drugs specifically designed to protect the heart.

What the 2026 Extension Added

The 2026 data deepened those findings. The benefit not only held steady but continued to widen over time. People who stayed on the medication for three or more years showed sustained reductions in cardiovascular events, and the protective effect appeared independent of how much weight a person actually lost. That detail matters enormously. It suggests semaglutide does something directly to the cardiovascular system, beyond the indirect benefits that come from carrying less body weight.

Researchers observed improvements in inflammatory markers, reductions in apoB-containing lipoproteins, and better blood pressure control among active treatment groups. These are concrete physiological changes that explain why the heart benefits accumulate even before significant weight loss occurs.

Another important finding from the extension: the drug proved safe over prolonged use. Discontinuation rates remained low, and serious adverse events were no more common in the treatment group than in the placebo group. This matters for people who need to stay on a medication for years or potentially for life.

Why This Matters for Everyday Patients

Cardiovascular disease remains the leading cause of death worldwide. Anyone who has watched a parent, a partner, or a friend navigate the aftermath of a heart attack knows how profoundly it disrupts life. The SELECT data offers something genuinely new: a medication that, when added to standard care, meaningfully lowers the risk of these events in people who are already struggling with weight and heart health.

This does not replace diet, exercise, or the other foundations of cardiovascular care. But it adds a powerful layer on top of those habits. For people who have tried lifestyle changes alone and still carry significant cardiovascular risk, semaglutide now has a proven place in the conversation.

Managing a condition that affects both weight and heart health takes more than a prescription, though. It takes daily attention, regular check-ins, and a way to connect the choices someone makes to the numbers that matter. That is where tools like Ozempro fit in. The app helps users track the metrics that matter alongside their treatment, keeping everything in one place so appointments become conversations instead of guesswork. You can learn more about how it supports people on GLP-1 therapy by clicking here.

The Bigger Picture for GLP-1 Medications

The SELECT trial repositioned semaglutide from a diabetes and obesity drug into a cardiovascular medication with broad reach. Regulatory agencies have taken note, and several have expanded or are reviewing approvals to include cardiovascular risk reduction as a primary indication. Insurance companies are slowly following, which matters because coverage determines who can actually access these benefits.

The field is moving fast. Researchers are studying whether other GLP-1 receptor agonists show the same cardiovascular advantages, and early data on tirzepatide suggests the class effect is real. Combination therapies are also in development, aiming to amplify the benefits while managing side effects like nausea and gastrointestinal discomfort, which remain the main reasons people stop treatment.

What stays constant is the need for individualized care. These medications are not for everyone, and the decision to start one should involve a honest conversation with a healthcare provider about risks, benefits, and what success actually looks like for each person.

Putting It All Together

If you or someone you know is managing weight and also living with cardiovascular concerns, the evidence now clearly supports discussing GLP-1 therapy with a doctor. The 2026 SELECT data removed any lingering doubt that this class of medication delivers real heart protection, not just thinner waistlines.

The path forward usually involves more than medication alone. Tracking progress, staying consistent with follow-up appointments, and building habits that support both weight and heart health all compound over time. Ozempro was built to support exactly that kind of ongoing, structured engagement with your health. Many users find that having a dedicated space to log symptoms, weight, and other markers makes it easier to have productive conversations with their care team and stay motivated between visits.

The science has caught up with what many patients already suspected. These medications do more than help people lose weight. They help people live longer, healthier lives.